Nanoparticles: “magic bullets” for targeting the immune system

Seminars in Immunology

Volumn 34, Issue , 2017, Pages 1-2

  Granucci, Francesca ^a   Prosperi, Davide ^a,b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; INFLAMMASOME; NANOPARTICLE; PATTERN RECOGNITION RECEPTOR; VACCINE;

AUTOIMMUNE DISEASE; DEGENERATIVE DISEASE; EDITORIAL; IMMUNE SYSTEM; IMMUNOTOXICITY; INFLAMMATORY DISEASE; INNATE IMMUNITY; MALIGNANT NEOPLASM; NANOMEDICINE; NANOTECHNOLOGY; ANIMAL; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MOLECULARLY TARGETED THERAPY; NEOPLASM;

ANIMALS; HUMANS; IMMUNE SYSTEM; IMMUNITY, INNATE; IMMUNOMODULATION; IMMUNOSUPPRESSION; MOLECULAR TARGETED THERAPY; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASMS;

EID: 85035078573     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2017.10.002     Document Type: Editorial

References (9)

1. Shi, J.J., Kantoff, P.W., Wooster, R., Farokhzad, O.C., Cancer nanomedicine: progress, challenges and opportunities. Nat. Rev. Cancer 17 (2017), 20–37.
2. Yaari, Z., da Silva, D., Zinger, A., Goldman, E., Kajal, A., Tshuva, R., Barak, E., Dahan, N., Hershkovitz, D., Goldfeder, M., Roitman, J.S., Schroeder, A., Theranostic barcoded nanoparticles for personalized cancer medicine. Nat. Commun., 7, 2016, 13325.
3. Blanco, E., Shen, H., Ferrari, M., Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 33 (2015), 941–951.
4. Colombo, M., Fiandra, L., Alessio, G., Mazzucchelli, S., Nebuloni, M., De Palma, C., Kantner, K., Pelaz, B., Rotem, R., Corsi, F., Parak, W.J., Prosperi, D., Tumour homing and therapeutic effect of colloidal nanoparticles depend on the number of attached antibodies. Nat. Commun., 7, 2016, 13818.
5. Santini, B., Zanoni, I., Marzi, R., Cigni, C., Bedoni, M., Gramatica, F., Palunga, L., Corsi, F., Granucci, F., Colombo, M., Cream formulation impact on topical administration of engineered colloidal nanoparticles. PLoS ONE, 10, 2015, e0126366.
6. Eifler, A.C., Thaxton, C.S., Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study. Methods Mol Biol 726 (2011), 325–338.
7. Chow, Ek-H., Ho, D., Cancer Nanomedicine: From Drug Delivery to Imaging. Sci. Transl. Med., 5, 2013, 216rv4.
8. Trevaskis, N.L., Kaminskas, L.M., Porter, C.J.H., From sewer to saviour – targeting the lymphatic system to promote drug exposure and activity. Nat. Rev. Drug Discov. 14 (2015), 781–803.
9. Paulis, L.E., Mandal, S., Kreutz, M., Figdor, C.G., Dendritic cell-based nanovaccines for cancer immunotherapy. Current Opin. Immunol 25 (2013), 389–395.